Consortia

Establishing Consortia

From its beginning, creation of consortia has been fundamental to the work of Critical Path Institute. The FDA, in 2006, after consulting with experts in industry, government, academia and patient advocacy groups, identified the work that is needed, i.e., the 76 projects on the Critical Path Opportunity List.¹ Many of these projects require collaboration, and the Critical Path Institute has been an international leader in forming successful collaborations.² One of C-Path's first steps was to reach agreement with the FDA and leading industry scientists on what processes they would use to advance the Critical Path Initiative. The resulting process is transparent and entrepreneurial, driven by swift, thoughtful decisions and accountable to timely, predetermined milestones.

The challenge was to create a productive environment among private sector competitors while balancing their needs with those of the FDA, academic scientists, and the public health. Please click here for more information.

1. Food and Drug Administration. Critical Path Opportunities Report and List; http://www.fda.gov/oc/initiatives/criticalpath/reports/opp_list.pdf. 3-16-2006. Internet Communication
2. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med 2008; 59:1-12.